HCA
PLRX icon

Harbor Capital Advisors’s Pliant Therapeutics PLRX Stock Holding History

Harbor Capital Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,801
Closed -$1.26M – 1506
2024
Q4 		$1.26M Buy
95,801
+3,822
+4% +$52.2K 0.06% 410
2024
Q3 		$1.03M Buy
91,979
+64,422
+234% +$806K 0.04% 452
2024
Q2 		$296K Buy
27,557
+18,977
+221% +$245K 0.02% 611
2024
Q1 		$128K Buy
+8,580
New +$142K 0.02% 694
2023
Q3 		– Sell
-717
Closed -$13K – 596
2023
Q2 		$13K Buy
+717
New +$17K ﹤0.01% 629

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Harbor Capital Advisors's PLRX Position: Q1 2025 in Review

Harbor Capital Advisors sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 95,801 shares — an estimated $1.26M sold.

Harbor Capital Advisors first reported a position in PLRX in Q2 2023 and held it in 5 quarters. The position peaked at $1.26M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Harbor Capital Advisors reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 95,801 Pliant Therapeutics shares in Q1 2025, an estimated $1.26M.
  • Harbor Capital Advisors first reported a position in Pliant Therapeutics in Q2 2023 and held it in 5 quarters.
  • Harbor Capital Advisors's Pliant Therapeutics position peaked at $1.26M in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Harbor Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.